Most Recent
Pitcher Partners has lost its appeal of a decision that refused to stay a lawsuit over the accounting firm’s alleged involvement in race car driver Max Twigg’s misappropriation of $127 million from his family.
Ernst & Young has been hit with a discrimination suit by a former Asia Pacific director, who alleges she was fired after making complaints of bullying, harassment and discrimination.
Former G8 Education chair Jennifer Hutson has lost an appeal of a decision that found she was not unlawfully examined by the corporate regulator over the childcare company's $162 million hostile takeover bid for Affinity Education Group.
Virgin Australia has settled a lawsuit brought by its former chief pilot alleging the airline sacked him for complaining of bullying and harassment by its CEO.
A shareholder class action that was filed in the wake of the banking royal commission over AMP’s fees-for-no-service practices has settled for $110 million.
Qantas faces a class action on behalf of hundreds of thousands of customers who allegedly never received refunds after flights were cancelled during the COVID-19 pandemic.
A Star Entertainment joint venture has been hit with a lawsuit by the Queensland arm of Multiplex Constructions over alleged costs overruns in the construction for a multi-billion-dollar resort in Brisbane.
A Deloitte partner has brought legal action against a Sydney builder over variations to a $1.5 million contract to renovate his house in the waterfront suburb of Balmain, claiming the increases were meant as “cash support” for the construction business.
A judge has rejected a request by lawyers for Seven and the TV network's billionaire chairman, Kerry Stokes, to issue a correction to his published decision ordering the production of over 8,600 emails exchanged with Ben Roberts-Smith’s lawyers in a defamation case.
Novartis has lost its bid to have Pharmacor’s claim that its patent for a blood pressure drug is invalid decided ahead of a main trial where the Swiss pharmaceutical giant will allege the generic drug maker is threatening to infringe its patent.